甲基多巴原发性高血压。
文章的细节
-
引用
复制到剪贴板 -
Mah GT, Tejani, Musini VM
甲基多巴原发性高血压。
科克伦数据库系统启2009 10月7;(4):CD003893。cd003893.pub3 doi: 10.1002/14651858.。
- PubMed ID
-
19821316 (在PubMed]
- 文摘
-
背景:高血压和中风的风险增加有关,心肌梗死和充血性心力衰竭。甲基多巴是一种集中作用抗高血压药,常用的1970年代和80年代的血压控制。使用目前在很大程度上取代了抗高血压药物类用更少的副作用,但它仍然是用于发展中国家由于其低成本。回顾其相对有效性与安慰剂相比在代理和临床结果是有道理的。目的:量化甲基多巴相比安慰剂效应的随机对照试验(相关的)所有原因的死亡率、心血管疾病死亡率,严重不良事件,心肌梗死,中风,取款由于副作用,在原发性高血压患者的血压。必威国际app搜索策略:我们搜索以下数据库:科克伦中心注册的对照试验(1960 - 2009年6月),MEDLINE(2005 - 2009年6月),和EMBASE(2007 - 2009年6月)。书目引文检索的研究也被审查。没有语言的限制。选择标准:我们选择的相关研究原发性高血压患者。我们排除了继发性高血压或妊娠期高血压患者的研究。 DATA COLLECTION AND ANALYSIS: Two reviewers independently extracted data and assessed trial quality using the risk of bias tool. Data synthesis and analysis was performed using RevMan 5. Data for blood pressure were combined using the generic inverse variance method. MAIN RESULTS: Twelve trials (N=595) met the inclusion criteria for this review. None of these studies evaluated the effects of methyldopa compared to placebo on mortality and morbidity outcomes. Data for withdrawals due to adverse effects were not reported in a way that permitted meaningful meta-analysis. Data from six of the twelve trials (N=231) were combined to evaluate the blood pressure lowering effects of methyldopa compared to placebo. This meta-analysis shows that methyldopa at doses ranging from 500-2250 mg daily lowers systolic and diastolic blood pressure by a mean of 13 (95%CI 6-20) / 8 (95% CI 4-13) mmHg. Overall, the risk of bias was considered moderate. AUTHORS' CONCLUSIONS: Methyldopa lowers blood pressure to varying degrees compared to placebo for patients with primary hypertension. Its effect on clinical outcomes, however, remains uncertain.
DrugBank数据引用了这篇文章
- 药物